Intranuclear inclusions, in addition to intracytoplasmic inclusions, are frequent findings in some sporadic and/or genetic neurodegenerative diseases [1] . TDP-43 and FUS are nuclear proteins with multiple functions in mRNA processing, which have been involved in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) [2, 3, 4] . TDP-43 and FUS proteins shuttle between nucleus, and cytoplasm and defects in nucleocytoplasmic transport can contribute to these pathologies [5] . For example, in sporadic ALS and FTLD-FUS/ FET (fused in sarcoma/Ewing sarcoma/ TAF15) an accumulation of nuclear import protein Transportin 1 has been observed [6, 7] ; and proteins involved in nucleocytoplasmic transport are major components of TDP-43 aggregates [8] . On the other hand, alterations of nuclear membrane morphology and formation of clefts or invaginations are a frequent finding in FTLD and other neurodegenerative diseases [9] . In FTLD-TDP, the lentiform morphology of some nuclear inclusions ( Figure 1C ) -also named cat-eye inclusion -is reminiscent of nuclear clefts or invaginations (Figure 1A, D) . Similarly, the nuclear vermiform inclusions observed in aFTLD-U, a subtype of FTLD-FET, also mimic the morphology of nuclear clefts. This suggests that a fraction of TDP-43 and FUS proteins may accumulate within the nuclear clefts or invaginations and form a subtype of intranuclear inclusions characteristic of the disease, that may result into a cell-specific and disease-characteristic transcriptomic pattern.
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Nuclear clefts or invaginations are visible on HE-stained sections but are better identified by immunohistochemistry for the nuclear membrane protein lamin B1 ( Figure  1B) . However, TDP-43 cat-eye type nuclear inclusions do not necessarily contain nor are surrounded by the nuclear membrane on double immunofluorescence with lamin B1 in the case illustrated here ( Figure 1E ). This finding might suggest an alteration of the nuclear transport structure in neurons harboring apparently intranuclear inclusions. Alternatively, although defects in nucleocytoplasmic transport can contribute to this pathology, nuclear TDP-43 inclusions may develop independently of the nuclear membrane clefts.
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